Press Releases CombiGene AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 07:36:28 13/05/2024 pm IST			5-day change	1st Jan Change
3.48 ^SEK	-2.25%		-3.87%	+29.37%

13/03	CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries	CI
21/02	Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	CI

BioStock: CombiGene's pain programme takes important steps forward	03/05	AQ
CombiGene AB (publ) publishes annual report for 2023	26/04	AQ
Notice of Annual General Meeting in CombiGene AB (publ)	18/04	AQ
BioStock: CombiGene's CEO comments on the patent approvals in Australia and India	20/03	AQ
CombiGene’s epilepsy project CG01 has been granted patent in two new countries	13/03	AQ
BioStock: Comments from Orphazyme on the investment in CombiGene	04/03	AQ
The Danish company Orphazyme has acquired 10% of the shares in CombiGene	21/02	AQ
Year-end report January-December 2023 CombiGene AB (Publ)	16/02	AQ
BioStock: CombiGene comments on the discontinued CGT2 project	02/02	AQ
CombiGene discontinues the preclinical development of the lipodystrophy project CGT2	01/02	AQ
CombiGene: "We continue to believe in the epilepsy project CG01"	16/01	AQ
CombiGene has regained the global rights to the epilepsy project CG01	13/01	AQ
BioStock: CombiGene comments on Eurostars funding	22/12	AQ
Eurostars contributes SEK 8,7 million to the financing of the COZY01 pain project	20/12	AQ
New issue of CombiGenes, no 5 2023	27/11	AQ
BioStock: CombiGene focuses on the pain project	15/11	AQ
Interim report January – September 2023 for CombiGene AB (publ)	10/11	AQ
BioStock: CombiGene has chosen CRO for the pain project	01/11	AQ
CombiGene chooses Charles River as preclinical toxicology partner for COZY01 pain project	31/23/31	AQ
CombiGene and Zyneyro choose initial indication in the COZY01 pain project	26/23/26	AQ

No results for this search